Delayed Nyse  -  03:59 2022-08-12 pm EDT
12.49 USD   +2.88%
08/08ANNOVIS BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
08/08Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
08/08ANNOVIS BIO : Announces Second Quarter 2022 Results and Provides Corporate Update - Form 8-K
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Annovis Bio : June 24, 2021Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards

06/24/2021 | 08:49am EDT

Thu, 24 Jun 2021

Berwyn, Pennsylvania, June 24, 2021 - Annovis Bio, Inc. (NYSE American: ANVS), ('Annovis' or the 'Company'), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria L. Maccecchini, Ph.D., was selected as a Life Sciences and Healthcare CEO finalist in the 2021 PACT Enterprise Awards.

Hosted by the Philadelphia Alliance for Capital and Technologies (PACT), whose vision is to be the go-to resource for fast growing companies and a driver of entrepreneurship and innovation in the Philadelphia region, the PACT Enterprise Awards is a two-night, hybrid event featuring an in-person celebration on June 29 and an online broadcast of the Enterprise Awards ceremony on June 30, presented by Fairmount Partners and KPMG.

The awards ceremony will take place from 4:30 p.m. to 5:30 p.m. ET on June 30 and can be viewed online:

As part of the 28th annual awards event, PACT hosted a panel, 'Legends and Leaders,' in which Dr. Maccecchini was a speaker. She participated in the discussion with past PACT Enterprise Awards Legend Honorees and other business leaders. The June 23 panel discussed the unique challenges and lessons learned from the past year as well as the current business environment and opportunities for the future.

Watch the PACT Legends and Leaders panel discussion:

Watch the PACT Enterprise Awards finalist announcement:

About Annovis Bio Inc.

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website:

Forward Looking Statements

Statements in this press release contain 'forward-looking statements' that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'expect,' 'believe,' 'will,' 'may,' 'should,' 'estimate,' 'project,' 'outlook,' 'forecast' or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dave Gentry, CEO

RedChip Companies Inc.



Annovis Bio Inc. published this content on 24 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 June 2021 12:48:02 UTC.

© Publicnow 2021
All news about ANNOVIS BIO, INC.
08/08ANNOVIS BIO, INC. Management's Discussion and Analysis of Financial Condition and Resu..
08/08Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended ..
08/08ANNOVIS BIO : Announces Second Quarter 2022 Results and Provides Corporate Update - Form 8..
08/08Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
08/01Annovis Bio to Participate on Alzheimer's Association International Conference Panel
07/14Annovis Bio to Present at the Alzheimer's Association International Conference
07/07SECTOR UPDATE : Health Care Stocks Gain Premarket Thursday
07/07SECTOR UPDATE : Health Care
07/07Annovis Bio Shares Rise 8% After FDA Allows Buntanetap Trial to Proceed
07/07Annovis Bio Says FDA Gives Permission to Proceed With Phase 3 Trial of Early Parkinson'..
More news
Analyst Recommendations on ANNOVIS BIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -30,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,37x
Yield 2022 -
Capitalization 102 M 102 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 3
Free-Float 69,1%
Duration : Period :
Annovis Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANNOVIS BIO, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 12,49 $
Average target price 31,50 $
Spread / Average Target 152%
EPS Revisions
Managers and Directors
Maria-Luisa Maccecchini President, Chief Executive Officer & Director
Jeffrey B. McGroarty Chief Financial Officer
Michael B. Hoffman Chairman
Cheng Fang Senior Vice President-Research & Development
Claudine E. Bruck Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANNOVIS BIO, INC.-28.95%102
GILEAD SCIENCES, INC.-13.29%78 912
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968